FAM160A1 Inhibitors
Chemical inhibitors of FAM160A1 function through various mechanisms to disrupt the normal cell cycle regulation and other cellular processes. Alsterpaullone, a cyclin-dependent kinase (CDK) inhibitor, impedes the activity of CDKs, which are pivotal in cell cycle progression. The inhibition of these kinases by alsterpaullone can lead to cell cycle arrest, thereby affecting FAM160A1's associated functions. Similarly, roscovitine targets CDK1, CDK2, and CDK9, integral components of cell cycle regulation. By hindering these kinases, roscovitine can directly impact the functionality of FAM160A1. Olomoucine, with its selective inhibition of CDK1, CDK2, and CDK5, can disrupt the cell cycle control and consequently the activity of FAM160A1. Flavopiridol broadly inhibits CDKs, leading to cell cycle arrest at various points, which can impinge on the cellular functions involving FAM160A1. Purvalanol A, another inhibitor, is known for its potency against CDK1, CDK2, and CDK5, and by such action, it can cause a blockade of FAM160A1 activity.
Furthermore, indirubin-3'-monoxime extends its inhibitory properties to CDKs and GSK-3beta, altering cell cycle dynamics and cellular signaling, which can suppress the function of FAM160A1. Paullone compounds, including alsterpaullone, target CDKs and are capable of interfering with the cellular functions essential to FAM160A1 activity. Butyrolactone I, selective for CDK2, can impair the activity of FAM160A1 by disrupting cell cycle-dependent functions. 5-Iodotubercidin, which inhibits adenosine kinase and a spectrum of other kinases, can interrupt signaling pathways that involve FAM160A1. Kenpaullone, by targeting both CDKs and GSK-3beta, can interfere with critical signaling pathways and cellular processes, inhibiting FAM160A1. Milciclib, a multi-kinase inhibitor, can interfere with cell cycle progression and other processes essential for FAM160A1 activity. Lastly, ribociclib's selective inhibition of CDK4/6, crucial for the G1 phase of the cell cycle, can lead to cell cycle arrest and consequent inhibition of FAM160A1 functions that depend on this phase.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are part of the cell cycle regulation mechanism. Inhibition of CDKs can lead to arrest of the cell cycle, thereby inhibiting the activity of family with sequence similarity 160, member A1 (FAM160A1) which is involved in cellular processes that are dependent on cell cycle progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine serves as an inhibitor of CDKs, particularly CDK1, CDK2, and CDK9, which are integral to the regulation of the cell cycle. By impeding these kinases, the chemical can inhibit the function of FAM160A1 if it is involved in cell cycle-dependent pathways. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine, another CDK inhibitor, selectively targets CDK1, CDK2, and CDK5, which play a pivotal role in cell cycle control. The inhibition of these kinases can impair the function of FAM160A1 by disrupting cell cycle-related processes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits various CDKs and can induce cell cycle arrest. By disrupting the normal progression of the cell cycle, Flavopiridol can inhibit the activity of FAM160A1, particularly if its function is linked to cell cycle phases. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDK1, CDK2, and CDK5, which are essential for cell cycle progression. This inhibition can lead to a functional blockade of FAM160A1 if its activity is intertwined with cell cycle events. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is known to inhibit CDKs and GSK-3beta, potentially leading to altered cell cycle dynamics and cellular signaling pathways. This modification of cellular processes can inhibit the function of FAM160A1. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $120.00 $504.00 | 1 | |
Butyrolactone I is a selective inhibitor of CDK2, which is involved in the regulation of the G1/S transition in the cell cycle. Inhibition of CDK2 can impair the activity of FAM160A1 by disrupting its cell cycle-dependent functions. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that also inhibits other kinases, potentially disrupting signaling pathways that FAM160A1 is a part of, leading to its functional inhibition. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone is a known inhibitor of CDKs and GSK-3beta. By inhibiting these kinases, kenpaullone can interfere with signaling pathways and cellular processes that are critical for the function of FAM160A1, thereby inhibiting its activity. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib is a multi-kinase inhibitor that targets various CDKs. The inhibition of these kinases can interfere with the cell cycle and other processes necessary for the functional activity of FAM160A1. | ||||||